Market
Scenario
Xanthoma
are also known as desmoid fibromatosis. These benign growths occur very rarely
in the general population. Desmoid tumor usually develops in the fibrous tissue
of the body, commonly in the arms, legs or midsection, and sometimes in the
head and neck. The term desmoid was derived from the Greek word desmos, which
means tendonlike. Xanthoma appear as well-differentiated, and firm overgrowths
of fibrous tissue. According to the U.S National Library of Medicine, Xanthoma
are very rare as the rate of occurrence is estimated to be 1 to 2 per 500,000
people worldwide. It is also stated that nearly 900 to 1,500 new cases are
registered per year in the United States. Tumors associated with familial
adenomatous polyposis (FAP) are less common than sporadic Xanthoma.
On
molecular level, desmoid tumor is characterized by one of the two mutations in
the gene i.e. mutations in the adenomatous polyposis coli (APC) gene, or in the
β-catenin gene, CTNNB1. During diagnostic procedures CTNNB1 mutation is
detected, especially, when pathological differential diagnosis is difficult.
According
to the Desmoid Rare Foundation, individuals within the age group of 15 and 60
are more likely to get affected by this condition. It is also stated that the
condition is more prevalent in women than in men (2:1).
For the
diagnosis of desmoid tumor there are many non-invasive methods available to
detect desmoid tumor which include ultrasound, MRI scan, and CT scan. The
actual diagnosis of this tumor can be made only after examining a small piece
of the tumor by a trained pathologist.
The
symptoms of Xanthoma include a painless swelling or lump, pain and obstruction
of the bowels, limping, pain caused by compressed nerves or muscles, and
others.
The most
commonly used treatment options for Xanthoma are anti-inflammatory medication,
Chemotherapy, Hormone therapy, and surgery among others. Various new therapies
are under investigation such as Angiogenesis inhibitors, and Chemotherapy
agents. As mutations in the CTNNB1 gene is found to be most commonly occurring
in desmoid tumor. So, it is expected that very soon mutation analysis be used
to predict the risk of recurrence and to aid in designing individual therapies.
Notably,
the market is expected to expand in the near future due to rising demand of
effective chemotherapeutic agents, high unmet needs of current treatment, and
increase in research and development expenditure.
Despite
these drivers, there are some issues associated with Xanthoma market. High cost
of treatment & management of Xanthoma and related disorders, and lack of
infrastructure in the middle and low income countries may hamper the growth of
the market.
It is
estimated that Xanthoma market is expected to grow at a CAGR 4.5% during the
forecast period of 2017-2023.
Segmentation
The Xanthoma
market is segmented on the basis of diagnosis, treatment, and end-user.
On the
basis of diagnosis, market is segmented into biopsy, electron microscopic
examination, immunohistochemical analysis, others
On the
basis of treatment, market is classified into surgery, radiation therapy,
anti-inflammatory medication, hormone therapy, chemotherapy, novel
molecular-targeted therapy, others. Novel molecular-targeted therapy is further
segmented into gleevec based therapy, and sorafenib based therapy
On the
basis of end-user, market is segmented into hospital, clinics, and
others.
Regional
Analysis
The
Americas dominate the Xanthoma market owing to the rising awareness among
people, and increasing healthcare expenditure. As per the facts suggested by the
Centers for Disease Control and Prevention (CDC), it is found that out of total
annual healthcare expenditure, 86% is for people with chronic health conditions
in the United States. Furthermore, increasing participation of bigger players
and new marketers towards advancement in treatment approaches have also
attracted a great deal of attention.
Europe
holds the second position in the Xanthoma market. It is expected that the
support provided by government bodies for research & development and
improvement in reimbursement policies in healthcare will drive the market in
Europe region.
Asia
Pacific is the fastest growing Xanthoma market owing to the huge patient pool
and developing healthcare technology.
The
Middle East & Africa has the lowest market for Xanthoma market due to lack
of technical knowledge and poor medical facilities.
Key
Players
Some of
key the players in the market are Amgen Inc., Novartis AG, Abbott Laboratories,
Bayer AG, AbbVie Inc., Beckman Coulter Inc., Stryker Corporation, Debiopharm
Group, F. Hoffmann-La Roche Ltd, and others.
Detailed Table
of Contents:
1. Report Prologue
2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
...Continued
About US:
Market
Research Future (MRFR), enable customers to unravel the complexity of various industries
through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw
Research Reports (3R), Continuous-Feed Research (CFR), and Market Research
& Consulting Services.
Contact
Us:
Market
Research Future
Office
No. 528, Amanora Chambers
Magarpatta
Road, Hadapsar,
Pune
- 411028
Maharashtra,
India
Phone:
+1 646 845 9312
Email:
sales@marketresearchfuture.com